Short Interest in Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Declines By 65.6%

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) was the recipient of a large drop in short interest in the month of September. As of September 15th, there was short interest totaling 10,600 shares, a drop of 65.6% from the August 31st total of 30,800 shares. Based on an average daily volume of 134,000 shares, the short-interest ratio is presently 0.1 days. Based on an average daily volume of 134,000 shares, the short-interest ratio is presently 0.1 days.

Oncotelic Therapeutics Stock Performance

Oncotelic Therapeutics stock opened at $0.07 on Thursday. Oncotelic Therapeutics has a fifty-two week low of $0.02 and a fifty-two week high of $0.08. The stock has a market cap of $30.16 million, a P/E ratio of -6.89 and a beta of -0.69. The firm’s fifty day moving average price is $0.05 and its 200-day moving average price is $0.06.

Oncotelic Therapeutics Company Profile

Oncotelic Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.